Company Overview and News
Chicago, IL – June 22, 2018 – Today, Zacks Investment Ideas feature highlights Features: CRISPR Therapeutics (CRSP - Free Report) , Editas Medicine (EDIT - Free Report) andIntellia Therapeutics (NTLA - Free Report) .
NTLA EDIT MS.PRI MS.PRK MPX MS.PRE CRSP MS.PRF MS.PRG MS MS.PRA FIVE
Anika Therapeutics (ANIK) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combination anti-inflammatory formula that combines hyaluronic acid (‘HA) with a steroid (triamcinolone hexacetonide). HA serves as a lubricant for arthritic joints.
NTLA CYAD AMGN ANIK PSTI CRSP SRPT MDWD CANF AMPH NVUS RSLS ALXN ALNA KALA CYAD CLBS PRTA PSTIW
By far the most exciting real-time revolution unfolding in Biotechnology is CRISPR gene editing. And the past few months have provided plenty of excitement for Biotech investors as the three public companies who are pure-play manifestations of the technology have made some dramatic moves -- on good news and bad.
NTLA EDIT IP GILD INPAP CRSP
The Regents of the University of California (UC), the University of Vienna, and Emmanuelle Charpentier, Ph.D., of the Max-Planck Institute in Berlin, have been granted U.S. Patent No. 10,000,772 for intellectual property related to CRISPR/Cas9 genome editing technology. [Genetic Literacy Project]
ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, Ph.D. (collectively, “UC”), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome editing technology, were granted U.
NTLA VRTX CRSP
Investors can easily create a stock and bond “set-and-forget-it,” diversified, lazy exchange-traded fund (ETF) portfolio — then kick back and relax. But what if you want more than just the typical stock and bond ETFs in your affordable investment portfolio? There’s a case to be made for traveling off the beaten ETF path. Consider adding alternative asset classes — commodities, sector bets, smart beta funds and more — without breaking the bank.
PCG NTLA F MS.PRE MS.PRF MS.PRG ILMN MS.PRA MS.PRI MU GM.WS.A MS.PRK GM.WS.B GM.WS.C MS GM GM.WSB
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP
Shares of CRISPR Therapeutics AG CRSP, -12.65% tumbled 12% in active midday trade Monday, after a STAT report that edited cells might cause cancer. Volume spiked to 3.1 million shares, already nearly double the full-day average of about 1.7 million shares. CRISPR Therapeutics is a gene editing company that develops treatments for serious diseases using its proprietary CRISPR/Cas9 platform, which allow precise and directed changes to genomic DNA.
Looking for broad exposure to the Technology - Broad segment of the U.S. equity market? You should consider the ARK Innovation ETF (ARKK - Free Report) , a passively managed exchange traded fund launched on 10/31/2014.
NTLA SSYS AMZA ARKK
Chicago, IL – June 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AAC Holdings, Inc. (AAC - Free Report) , Bryn Mawr Bank Corporation (BMTC - Free Report) , Lindblad Expeditions Holdings, Inc. (LIND - Free Report) , Orchid Island Capital, Inc.
NTLA LINDW DB UAA JBLU CLAC ORC AAC UA BRK.A CLACW DG CLACU BMTC LIND SALM
12h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
13h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET